We intend to focus our search on “omnichannel” businesses — technology-enabled cross-channel retail and consumer services — including the direct-to-consumer (“DTC”) / e-commerce retail, consumer healthcare, consumer marketplaces, consumer services and related sectors in North America with enterprise values from $1 billion to $2.5 billion. (Note: This IPO was downsized again at pricing: 20 million units priced at $10. The size of […]

We intend to focus our search on companies emerging from a reorganization or a distressed situation with an enterprise value of approximately $400 million to $1 billion. Stephen C. Smith, our chairman and CEO, founded Seaport Global Asset Management LLC (“SGAM”), an SEC registered investment advisor, in August 2017. He is SGAM’s chief executive officer. […]

We intend to initially focus on target businesses in the renewables, infrastructure, energy and construction and industrial industries. We will seek to capitalize on the experience of our management team in consummating an initial business combination. Eric S. Rosenfeld, our Chief SPAC Officer, and David D. Sgro, our Chief Executive Officer, have led six prior […]

We intend to focus our search on defense, government service and aerospace businesses, which complements the expertise of our management team, directors and the Pine Island Capital Partners team. Our sponsor is an affiliate of Pine Island Capital Partners, a private equity firm established in 2018 by John A. Thain and Philip A. Cooper. John […]

We intend to capitalize on the ability of our management team to identify, acquire and operate a business at the intersection of the healthcare and technology industries, though we reserve the right to pursue an acquisition opportunity in any business or industry.

We are a leading global provider of mission-critical sterilization and lab testing and advisory services to the medical device and pharmaceutical industries. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for […]

We are a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Our immuno-oncology product candidates include a clinical-stage monoclonal antibody and a portfolio of bispecific antibodies. These product candidates are designed to address three critical components required for an effective immune response […]

We are a leading regional food retailer based on revenue and number of stores we operate with a long-standing history in the Southeastern United States, serving highly attractive markets throughout Florida, Georgia, Alabama, Louisiana and Mississippi. We operate 420 stores under the “Winn-Dixie,” “Harveys” and “Fresco y Más” supermarket banners. We believe we are the […]

We are a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy […]

  We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Leveraging our deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, we have built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, […]